Mesothelioma: closer to the target?
Mené sur 222 patients atteints d'un mésothéliome pleural malin, cet essai de phase III évalue, du point de vue du délai avant progression, le thalidomide en traitement d'entretien après une chimiothérapie de première ligne
Patients and families of patients with mesothelioma do not ask for much. They have no time to waste on therapies that have proven useless for extending survival when confronted with the incredibly small portfolio of efficacious treatment options in this disease. For this reason, Wieneke Buikhuisen and colleagues' long awaited, superbly designed and executed switch maintenance trial with thalidomide 1 is a landmark achievement in mesothelioma, despite the fact that it failed to show improvement in ...
The Lancet Oncology , commentaire, 2012